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Dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4 and IL-
13 signaling, is currently approved for the treatment of atopic derma-
titis (AD). Effective treatment of hand eczema with dupilumab has
been reported previously in case series, two small retrospective
cohorts, and one prospective observational study including atopic, irri-
tant and vesicular hand eczema subgroups.1-4 However, the effect of
dupilumab on isolated hyperkeratotic hand eczema (HHE) has not yet
been described.
METHODS
Three patients with moderate to severe HHE were treated with
dupilumab 600 mg subcutaneously on day 1, followed by 300 mg sub-
cutaneously every 14 days. A minimum washout of topical treatment
of 2 weeks was applied. All patients underwent patch testing and no
relevant contact allergies were detected. Concomitant fungal infec-
tions were ruled out and the diagnosis HHE was confirmed by
histopathology.
Age, sex, disease duration, occupation, smoking status, treatment
history, exposure to irritants, atopic comorbidities, and specific immu-
noglobulin E (IgE) inhalant allergens were assessed at baseline. Thera-
peutic response was evaluated every 4 weeks up to 16 weeks of
treatment by the hand eczema severity index (HECSI),5 the photo-
graphic guide,6 clinical photographs, Quality of Life in Hand Eczema
Questionnaire (QOLHEQ),7 and the weekly average of the number
rating scale (NRS) for pain and pruritus (0–10, with 10 being the worst
pruritus/pain).
RESULTS
Two males and one female, of respectively 65, 47 and 65 years of
age, were treated (Appendix S1). All of them were previously treated
with ultra-potent topical corticosteroids and at least two different sys-
temic therapies, alitretinoin, among others. Case 1 had an inadequate
response to alitretinoin, Cases 2 and 3 were intolerant to alitretinoin.
None of the patients had a history of AD. Case 1 was a current
smoker with 88 pack-years and experienced occupational exposure to
irritants as a bricklayer by friction and wearing gloves during part of
the day. All lesional skin biopsies presented identical histopathologic
features (Appendix S2).
Two patients (case 2 and 3) had already major improvement after
4 weeks and symptoms cleared completely after 16 weeks of treat-
ment. Case 1 noticed minimal clinical improvement, however, there
was an improvement in itch and quality of life (Figure 1).
DISCUSSION
The pathogenesis of HHE remains largely unclear. A previous study
on the gene and protein expression of hand eczema, including
15 patients with chronic hyperkeratotic-fissured hand eczema
showed, among others, increased proliferative cell activity indicated
by Ki-67, and a decreased expression of the terminal differentiation
marker loricrin in palmar lesional skin biopsies, which was normalised
following alitretinoin treatment.8 Another study showed an
upregulation in keratinocyte host defence mechanism proteins
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(S100A7/S100A8/S100A9) in six patients with chronic hand eczema,
including different subtypes, compared to healthy control skin.9 A
study on protein expression in seven patients with HHE, showed also
increased proliferative cell activity indicated by Ki-67 and a strong
upregulation of keratin (K)16 with, in addition, a decreased expression
of loricrin in lesional palmar skin compared to perilesional skin and
healthy control skin.10 In patients with AD treated with dupilumab a
significantly reduced gene expression of K16 and MKi67, a reduced
expression of S100As genes, and an increase in loricrin expression is
seen after treatment.11 Therefore, the good effect of dupilumab on
HHE could be explained by the similarities in the epidermal pathology
in patients with AD and HHE, including epidermal hyperproliferation
and an impaired epidermal barrier.
Lack of clinical improvement in Case 1 might be explained by his
occupational activities as a bricklayer, whereby hand eczema is also
caused by exposure to irritants and friction. To date, no consensus
has been reached on the classification system of hand eczema. It
depends on the classification system if HHE is classified as an
endogenous subtype without identifiable cause12 or if it could have
contributing identifiable causes such as exposure to irritants.13 How-
ever, only one case report published the successful dupilumab treat-
ment of occupational irritant hand dermatitis14 However, it is possible
that the role of different cytokines (including IL-4) is affected by sev-
eral other factors, such as the identity of the topical irritant or to what
extent the irritant factor contribute to the etiology. Another contrib-
uting factor to the lack of clinical effect could be that the patient was
smoking.
Previous literature has showed successful results of dupilumab on
hand eczema in patients treated for AD1 and in individuals with iso-
lated vesicular hand eczema.2,4 In view of the good effect of
dupilumab on HHE as well, it might be hypothesized that, despite the
differences in phenotype, there are similarities in endotype and under-
lying pathogenesis with an IL-4/IL-13 driven inflammation between
different subtypes of hand eczema. Therefore, dupilumab could be
considered as an effective treatment of severe hand eczema, regard-
less of subtype. This should be investigated in future studies.
F IGURE 1 Clinical improvement of the three cases after 16 weeks of dupilumab treatment. (1A, 2A,3A) case 1, 2 and 3 at baseline, (1B, 2B,
3B) case 1, 2, 3 after 16 weeks of treatment
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